Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 287

1.

Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.

Theisen ER, Pishas KI, Saund RS, Lessnick SL.

Oncotarget. 2016 Apr 5;7(14):17616-30. doi: 10.18632/oncotarget.7124. Review.

2.

Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.

Sankar S, Theisen ER, Bearss J, Mulvihill T, Hoffman LM, Sorna V, Beckerle MC, Sharma S, Lessnick SL.

Clin Cancer Res. 2014 Sep 1;20(17):4584-97. doi: 10.1158/1078-0432.CCR-14-0072. Epub 2014 Jun 24.

3.

Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.

Kovar H.

Expert Opin Ther Targets. 2014 Nov;18(11):1315-28. doi: 10.1517/14728222.2014.947963. Epub 2014 Aug 27. Review.

PMID:
25162919
4.

Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.

Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, Lessnick SL.

Oncogene. 2013 Oct 17;32(42):5089-100. doi: 10.1038/onc.2012.525. Epub 2012 Nov 26. Erratum in: Oncogene. 2016 Nov 24;35(47):6155-6156.

5.

BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.

Loganathan SN, Tang N, Fleming JT, Ma Y, Guo Y, Borinstein SC, Chiang C, Wang J.

Oncotarget. 2016 Jul 12;7(28):43504-43517. doi: 10.18632/oncotarget.9762.

6.

Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.

Jacques C, Lamoureux F, Baud'huin M, Rodriguez Calleja L, Quillard T, Amiaud J, Tirode F, Rédini F, Bradner JE, Heymann D, Ory B.

Oncotarget. 2016 Apr 26;7(17):24125-40. doi: 10.18632/oncotarget.8214.

7.

Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.

Hensel T, Giorgi C, Schmidt O, Calzada-Wack J, Neff F, Buch T, Niggli FK, Schäfer BW, Burdach S, Richter GH.

Oncotarget. 2016 Jan 12;7(2):1451-63. doi: 10.18632/oncotarget.6385.

8.

Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.

Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, Khan J, Helman LJ.

Neoplasia. 2011 Feb;13(2):145-53.

9.

Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.

Hong SH, Youbi SE, Hong SP, Kallakury B, Monroe P, Erkizan HV, Barber-Rotenberg JS, Houghton P, Üren A, Toretsky JA.

Oncotarget. 2014 Jan 30;5(2):338-50.

10.

High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.

He T, Surdez D, Rantala JK, Haapa-Paananen S, Ban J, Kauer M, Tomazou E, Fey V, Alonso J, Kovar H, Delattre O, Iljin K.

Gene. 2017 Jan 5;596:137-146. doi: 10.1016/j.gene.2016.10.021. Epub 2016 Oct 17.

PMID:
27760381
11.

Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing's sarcoma.

Zöllner SK, Selvanathan SP, Graham GT, Commins RMT, Hong SH, Moseley E, Parks S, Haladyna JN, Erkizan HV, Dirksen U, Hogarty MD, Üren A, Toretsky JA.

Sci Signal. 2017 Oct 3;10(499). pii: eaam8429. doi: 10.1126/scisignal.aam8429.

PMID:
28974650
12.

Promiscuous partnerships in Ewing's sarcoma.

Sankar S, Lessnick SL.

Cancer Genet. 2011 Jul;204(7):351-65. doi: 10.1016/j.cancergen.2011.07.008. Review.

13.

Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor.

Osgood CL, Maloney N, Kidd CG, Kitchen-Goosen S, Segars L, Gebregiorgis M, Woldemichael GM, He M, Sankar S, Lessnick SL, Kang M, Smith M, Turner L, Madaj ZB, Winn ME, Núñez LE, González-Sabín J, Helman LJ, Morís F, Grohar PJ.

Clin Cancer Res. 2016 Aug 15;22(16):4105-18. doi: 10.1158/1078-0432.CCR-15-2624. Epub 2016 Mar 15.

14.

Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.

Gierisch ME, Pfistner F, Lopez-Garcia LA, Harder L, Schäfer BW, Niggli FK.

J Biol Chem. 2016 Dec 23;291(52):26922-26933. doi: 10.1074/jbc.M116.752063. Epub 2016 Nov 8.

15.

Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma.

Tosso PN, Kong Y, Scher L, Cummins R, Schneider J, Rahim S, Holman KT, Toretsky J, Wang K, Üren A, Brown ML.

J Med Chem. 2014 Dec 26;57(24):10290-303. doi: 10.1021/jm501372p. Epub 2014 Dec 12.

16.

Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.

Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, Helman LJ.

Clin Cancer Res. 2014 Mar 1;20(5):1190-203. doi: 10.1158/1078-0432.CCR-13-0901. Epub 2013 Nov 25.

17.

Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis.

Stoll G, Surdez D, Tirode F, Laud K, Barillot E, Zinovyev A, Delattre O.

Nucleic Acids Res. 2013 Oct;41(19):8853-71. doi: 10.1093/nar/gkt678. Epub 2013 Aug 8.

18.

Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage.

Lee HJ, Yoon C, Schmidt B, Park DJ, Zhang AY, Erkizan HV, Toretsky JA, Kirsch DG, Yoon SS.

Mol Cancer Ther. 2013 Nov;12(11):2591-600. doi: 10.1158/1535-7163.MCT-13-0338. Epub 2013 Aug 21.

19.

EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.

Mutz CN, Schwentner R, Aryee DNT, Bouchard EDJ, Mejia EM, Hatch GM, Kauer MO, Katschnig AM, Ban J, Garten A, Alonso J, Banerji V, Kovar H.

Oncotarget. 2017 Apr 11;8(15):24679-24693. doi: 10.18632/oncotarget.14976.

20.

FOXM1 is an oncogenic mediator in Ewing Sarcoma.

Christensen L, Joo J, Lee S, Wai D, Triche TJ, May WA.

PLoS One. 2013;8(1):e54556. doi: 10.1371/journal.pone.0054556. Epub 2013 Jan 24.

Supplemental Content

Support Center